MECOM gene overexpression in pediatric patients with acute myeloid leukemia

References

• Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2008; 66(3):181–193.
   PubMed Web of Science ®Google Scholar
• Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mortality. Cancer. 2014;120(16):2497–2506.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Ottaviani E, Buonamici S, et al. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. Haematologica. 2003;88(11):1221–1228.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Sato T, Yoshimi A, et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011;208(12):2403–2416.
   PubMed Web of Science ®Google Scholar
• Morishita K, Parker DS, Mucenski ML, et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;54(6):831–840.
   PubMed Web of Science ®Google Scholar
• Laricchia-Robbio L, Nucifora G. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis. 2008;40(2):141–147.
   PubMed Web of Science ®Google Scholar
• Haas K, Kundi M, Sperr WR, et al. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration . Genes Chromosomes Cancer. 2008;47(4):288–298.
   PubMed Web of Science ®Google Scholar
• Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942–949.
   PubMed Web of Science ®Google Scholar
• Roberto R, Capela DM, Moneeb AK, et al. Molecular approaches identify a cryptic MECOM rearrangement in a child with a rapidly progressive myeloid neoplasm. Cancer Genetics. 2018;221:25–30.
   Google Scholar
• Ho PA, Alonzo TA, Gerbing RB, et al. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children’s oncology group. Br J Haematol. 2013; 162(5):670–677.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using Real-Time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Rao X, Huang X, Zhou Z. An improvement of the 2^(–delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3(3):71–85.
   PubMedGoogle Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Yohe S. Molecular genetic markers in acute myeloid leukemia. J Clin Med. 2015;4(3):460–478.
   PubMed Web of Science ®Google Scholar
• Jo A, Mitani S, Shiba N, et al. High expression of EVI1 and MEL1 is a compelling poor prog. nostic marker of pediatric AML. Leukemia. 2015;29(5):1076–1083.
   PubMed Web of Science ®Google Scholar
• Matsuo H, Kajihara M, Tomizawa D, et al. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia . Haematologica. 2014;99(11):e225–e227.
   PubMed Web of Science ®Google Scholar
• Sadeghian MH, Rezaei Dezaki Z. Prognostic value of EVI1 expression in pediatric acute myeloid leukemia: a systematic review. Iran J Pathol. 2018; 12(3):294–300.
   Google Scholar
• Groschel S, Lugthart S, Schlenk RF, et al. HighEVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101–2107.
   PubMed Web of Science ®Google Scholar
• Saito Y, Nakahata S, Yamakawa N, et al. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. Leukemia. 2011;25(6):921–931.
   PubMed Web of Science ®Google Scholar
• Weer AD, Van der Meulen J, Rondou P, et al. EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol. 2011;154(3):337–348.
   PubMed Web of Science ®Google Scholar
• Heller G, Rommer A, Steinleitner K, et al. EVI1 promotes tumor growth via transcriptional repression of MS4A3. J Hematol Oncol. 2015;8:28.
   PubMed Web of Science ®Google Scholar